Harry Alcorn
Equibles does not estimate personal net worth.
About Harry Alcorn
The proxy statement of DiaMedica Therapeutics Inc. reports total compensation of $545,268 for Harry Alcorn in fiscal 2021, including a base salary of $302,112. Disclosed compensation is on record for 3 fiscal years.
Affiliation history
-
DiaMedica Therapeutics Inc. (DMAC)
Source not stated
Start not stated–2022-05-23
Company network
Executive compensation
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2021 | DiaMedica Therapeutics Inc. (DMAC) | Jr., Pharm.D.^^ Senior Vice President of Clinical Operations | $302,112 | $545,268 |
| 2020 | DiaMedica Therapeutics Inc. (DMAC) | Jr., Pharm.D.^^ Senior Vice President of Clinical Operations | $291,413 | $509,065 |
| 2019 | DiaMedica Therapeutics Inc. (DMAC) | Jr., Pharm.D.^^ Chief Medical Officer | $273,750 | $778,300 |
Recent activity
No call appearances or filed executive changes recorded yet.